XOMA CORPORATION (NASDAQ:XOMA) Files An 8-K Entry into a Material Definitive AgreementItem 1.01. Entry into a Material Definitive Agreement
On December6, 2017, XOMA Corporation (the “Company,” “XOMA” or “we”), through its wholly-owned subsidiary, XOMA (US) LLC, entered into a license agreement (“License Agreement “) with Rezolute, Inc. (“Rezolute”, formerly known as AntriaBio, Inc.) to which we granted an exclusive global license to Rezolute to develop and commercialize XOMA 358 (X358) for all indications. The Company and Rezolute also entered into a common stock purchase agreement (the “Purchase Agreement” and, together with the License Agreement, the “Transaction Documents”).
On March30, 2018, the Company amended the License Agreement and the Purchase Agreement originally entered into with Rezolute in December 2017.The License Agreement was amended to add terms specifying the financial responsibility for certain tasks related to the technology transfer.The Purchase Agreement was amended as follows: (1)adjusted the total shares due upon the Initial Closing (as defined in the Purchase Agreement) from $5million in value to 7,000,000 shares; (2)increase the shares due upon a Qualified Financing (as defined in the Purchase Agreement) from $7million in value to $8.5million in value; and (3)increase the shares due upon the 2019 Closing (as defined in the Purchase Agreement) from $7million in value to $8.5million in value.We anticipate the filing the amendments to the License Agreement and Purchase Agreement with our next Quarterly Report filing on Form 10-Q for the three month period ended March31, 2018.